Abstract
(E)-2′-deoxy-2′-(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate reductase, was selected for clinical development because of its novel mechanisms of action, and strong antitumor activity against experimental tumor models. This study was designed to determine the toxicities, maximum-tolerated dose (MTD), and pharmacokinetic profile of FMdC. FMdC was given orally for 5 consecutive days every 3 or 4 weeks in patients with advanced solid tumors. The starting dose was 8 mg/m2/day. Pharmacokinetic studies were carried out on days 1 through 5 of the first cycle. Ten patients with non-small cell lung cancer received 15 courses of FMdC at doses which were de-escalated from 8 mg/m2/day to 2 mg/m2/day because of unexpected severe toxicities at the starting dose level. Neutropenia was the dose-limiting toxicity. Thrombocytopenia and anemia were mild. Flu-like symptoms and fever were the common non-hematologic toxicities. The MTD was 4 mg/m2/day, since four of six patients developed grade 3–4 neutropenia. At the 4 mg/m2/day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), plasma clearance, and mean residence time on day 1 were 3.20 h, 15.8 ng/ml, 2.91 l/h/kg, and 4.03 h, respectively. The recommended dose for phase II studies with this schedule is also 4 mg/m2/day for 5 days. Further investigations are necessary to establish optimal dosing schedules and routes for the administration of FMdC.
Similar content being viewed by others
References
Elford H, Freese M, Passamani E, Morris H: Ribonucleotide reductase and cell proliferation. J Biol Chem 245: 5228-5233, 1970
McCarthy JR, Matthews DP, Stemerick DM, Huber EW, Bey P, Lippert BJ, Snyder RD, Sunkara PS: Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 20-deoxy-20-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J Am Chem Soc 113: 7439-7440, 1991
Yonetani Y, Mizukami T: Kinetic analysis of inhibition of human ribonucleotide reductase and DNA polymerase αby a new anticancer agent, (E)-20-deoxy-20-(fluoromethylene)cytidine. Proc Am Assoc Cancer Res 37: 405, 1996
Kyowa-Hakko Kogyo Co. L: Investigators Brochure of KW-2331 (in Japanese) Kyowa Hakko Kogyo, Co., Ltd. Tokyo, Japan, 1994
Kanazawa J, Takahashi T, Gomi K, Okabe M: Antitumor activity of (E)-'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Proc Am Assoc Cancer Res 36: 405, 1995
Sunkara PS, Zwolshen JH, Lippert BJ, Snyder RD, Matthews D, McCarthy JR: Antitumor activity of (E)-20-fluoromethylene-20-deoxycytidine (FMdC, MDL 101,731): a novel inhibitor of ribonucleotide reductase specific drugs. Proc Am Assoc Cancer Res 32: 415, 1991
Bitonti AJ, Dumont JA, Bush TL, Cashman EA, Cross-Doersen DE, Wright PS, Matthews DP, McCarthy JR, Kaplan DA: Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 54: 1485-1490, 1994
Bitonti AJ, Bush TL, Lewis MT, Sunkara PS: Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res 15: 1179-1182, 1995
Piepmeier JM, Rabidou N, Schold SC, Bitonti AJ, Prakash NJ, Bush TL: In vitroand in vivoinhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 56: 359-361, 1996
Wright PS, Cross Doersen D, Th'ng JPH, Guo XW, Crissman HA, Bradbury EM, Montogomery LR, Thompson FY, Loudy DE, Johnston JO, Bitonti AJ: A ribonucleotide reductase inhibitor, MDL-101,731, induced apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp Cell Res 222: 54-60, 1996
Mountain CF: A new international staging system for lung cancer. Chest 89: 225S-233S, 1996
World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland, World Health Organization, 1979
Ho DH-W: Distribution of kinase and deaminase of 1-b-Darabinofuranosylcytosine of tissues of man and mouse. Cancer Res 33: 2816-2820, 1973
Sunderman, FW: The clinical biochemistry of 50-nucleotidase. Ann Clin Lab Sci 20: 123-139, 1990
Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed, Marcel Dekker, New York, 1982, pp 85-111, pp 409-417
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T: A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4: 879-885, 1981
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991
Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 10: 165-170, 1992
O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee PG, Tarassoff PG, Von Hoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A: 417-418, 1994
Anderson H, Thatcher N, Walling J, Hansen H: A phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74: 460-462, 1996
Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535- 1540, 1994
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masuda, N., Negoro, S., Takeda, K. et al. Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule. Invest New Drugs 16, 245–254 (1998). https://doi.org/10.1023/A:1006126212481
Issue Date:
DOI: https://doi.org/10.1023/A:1006126212481